In vivo overexpression of synaptogyrin‐3 promotes striatal synaptic dopamine uptake in LRRK2R1441G mutant mouse model of Parkinson's disease

Leucine‐rich repeat kinase 2 (LRRK2) mutation is a common genetic risk factor of Parkinson's disease (PD). Presynaptic dysfunction is an early pathogenic event associated with dopamine (DA) dysregulation in striatum of the brain. DA uptake activity of DA uptake transporter (DAT) affects synaptic plasticity and motor and non‐motor behavior. Synaptogyrin‐3 (SYNGR3) is part of the synaptogyrin family, especially abundant in brain. Previous in vitro studies demonstrated interaction between SYNGR3 and DAT. Reduced SYNGR3 expression was observed in human PD brains with unclear reasons.

[1]  S. Ho,et al.  Transcriptional Regulation of the Synaptic Vesicle Protein Synaptogyrin-3 (SYNGR3) Gene: The Effects of NURR1 on Its Expression , 2022, International journal of molecular sciences.

[2]  D. Denys,et al.  Striatal dopamine signals are region specific and temporally stable across action-sequence habit formation , 2022, Current Biology.

[3]  Zhen Yan,et al.  Transcriptomic analysis of human brains with Alzheimer’s disease reveals the altered expression of synaptic genes linked to cognitive deficits , 2021, Brain communications.

[4]  M. Farrer,et al.  Dynamic control of the dopamine transporter in neurotransmission and homeostasis , 2021, NPJ Parkinson's disease.

[5]  D. Sarkar.  A Review of Behavioral Tests to Evaluate Different Types of Anxiety and Anti-anxiety Effects , 2020, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[6]  J. Kristensen,et al.  The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation , 2019, Neuropharmacology.

[7]  S. Ho,et al.  The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease , 2019, Translational Neurodegeneration.

[8]  Jing Wang,et al.  Identification of key genes and pathways for Alzheimer’s disease via combined analysis of genome-wide expression profiling in the hippocampus , 2019, Biophysics Reports.

[9]  Seth G. N. Grant,et al.  Synapse molecular complexity and the plasticity behaviour problem , 2018, Brain and neuroscience advances.

[10]  P. Verstreken,et al.  Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau , 2018, Neuron.

[11]  Kwang-Hyeon Liu,et al.  LRRK2 G2019S Induces Anxiety/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT1A Receptor Upregulation in Mice , 2018, The Journal of Neuroscience.

[12]  J. Shim,et al.  Oxidative stress and cellular pathologies in Parkinson’s disease , 2017, Molecular Brain.

[13]  Sohee Jeon,et al.  Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease , 2017, Science.

[14]  J. Segura-Aguilar,et al.  Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease? , 2017, ACS chemical neuroscience.

[15]  B. Wieringa,et al.  The SH-SY5Y cell line in Parkinson’s disease research: a systematic review , 2017, Molecular Neurodegeneration.

[16]  S. Ho,et al.  Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease , 2017, Scientific Reports.

[17]  S. Cragg,et al.  Striatal dopamine neurotransmission: regulation of release and uptake. , 2016, Basal ganglia.

[18]  E. Fedele,et al.  LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex , 2014, Front. Mol. Neurosci..

[19]  S. Ho,et al.  LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity , 2014, Annals of clinical and translational neurology.

[20]  M. Mattson,et al.  Communication breakdown: The impact of ageing on synapse structure , 2014, Ageing Research Reviews.

[21]  J. Foster,et al.  Mechanisms of dopamine transporter regulation in normal and disease states. , 2013, Trends in pharmacological sciences.

[22]  Robert E. Burke,et al.  Axon degeneration in Parkinson's disease , 2013, Experimental Neurology.

[23]  E. Belluzzi,et al.  Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2. , 2012, Biochemical Society transactions.

[24]  R. Tsien,et al.  Synaptic vesicle pools and dynamics. , 2012, Cold Spring Harbor perspectives in biology.

[25]  R. Leube,et al.  Synaptogyrin-dependent modulation of synaptic neurotransmission in Caenorhabditis elegans , 2011, Neuroscience.

[26]  E. Jazin,et al.  Age‐related changes in gene expression are accelerated in Alzheimer's disease , 2011, Synapse.

[27]  W. Wurst,et al.  LRRK2 Controls Synaptic Vesicle Storage and Mobilization within the Recycling Pool , 2011, The Journal of Neuroscience.

[28]  M. Askenazi,et al.  A QUICK Screen for Lrrk2 Interaction Partners – Leucine-rich Repeat Kinase 2 is Involved in Actin Cytoskeleton Dynamics* , 2010, Molecular & Cellular Proteomics.

[29]  R. Burke,et al.  Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.

[30]  F. Benes,et al.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. , 2009, Brain : a journal of neurology.

[31]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.

[32]  H. Sitte,et al.  Physical and Functional Interaction between the Dopamine Transporter and the Synaptic Vesicle Protein Synaptogyrin-3 , 2009, The Journal of Neuroscience.

[33]  R. Paylor,et al.  Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety , 2009, Psychopharmacology.

[34]  N. Hattori,et al.  LRRK2 regulates synaptic vesicle endocytosis. , 2008, Experimental cell research.

[35]  Steven Hahn,et al.  Transcriptional regulation , 2008, EMBO reports.

[36]  M. Dichter,et al.  Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity , 2008, Brain Research.

[37]  Y. Sugimoto,et al.  Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice. , 2007, Biological & pharmaceutical bulletin.

[38]  F. Penault-Llorca,et al.  Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification , 2007, Breast Cancer Research.

[39]  W. Jones,et al.  DNA methylation-dependent silencing of CST6 in human breast cancer cell lines , 2006, Laboratory Investigation.

[40]  E. Prinssen,et al.  A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. , 2006, European journal of pharmacology.

[41]  A. Schapira.  Non-motor symptoms , 2006 .

[42]  V. Sossi,et al.  Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. , 2006, Brain : a journal of neurology.

[43]  A. Beaudet,et al.  Normal biogenesis and cycling of empty synaptic vesicles in dopamine neurons of vesicular monoamine transporter 2 knockout mice. , 2004, Molecular biology of the cell.

[44]  Howard J Federoff,et al.  Dysregulation of Gene Expression in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Mouse Substantia Nigra , 2004, The Journal of Neuroscience.

[45]  C. Thaller,et al.  Characterization of synaptogyrin 3 as a new synaptic vesicle protein , 2004, The Journal of comparative neurology.

[46]  S. Kügler,et al.  Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area , 2003, Gene Therapy.

[47]  S. Ho,et al.  The aetiology of idiopathic Parkinson's disease , 2001, Molecular pathology : MP.

[48]  S. Amara,et al.  The Dopamine Transporter in Mesencephalic Cultures Is Refractory to Physiological Changes in Membrane Voltage , 2001, The Journal of Neuroscience.

[49]  Nikolaus R. McFarland,et al.  Striatonigrostriatal Pathways in Primates Form an Ascending Spiral from the Shell to the Dorsolateral Striatum , 2000, The Journal of Neuroscience.

[50]  T. Südhof,et al.  Synaptogyrins Regulate Ca2+-dependent Exocytosis in PC12 Cells* , 1999, The Journal of Biological Chemistry.

[51]  B. Roe,et al.  Characterization of the human synaptogyrin gene family , 1998, Human Genetics.

[52]  Alessandra Valentini,et al.  Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour , 1998, Behavioural Brain Research.

[53]  James M. Wilson,et al.  Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.

[54]  Jennifer A. Mangels,et al.  A Neostriatal Habit Learning System in Humans , 1996, Science.

[55]  I. Gyertyán,et al.  Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying , 1995, Behavioural pharmacology.

[56]  E. Masliah,et al.  Quantitative synaptic alterations in the human neocortex during normal aging , 1993, Neurology.

[57]  S. Handley,et al.  Evaluation of marble-burying behavior as a model of anxiety , 1991, Pharmacology Biochemistry and Behavior.

[58]  J. Volkmann,et al.  Parkinson disease , 2017, Nature Reviews Disease Primers.

[59]  S. Ho,et al.  Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease , 2017, Scientific Reports.

[60]  D. Langford,et al.  Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. , 2013, Methods in molecular biology.

[61]  J. Rawlins,et al.  T-maze alternation in the rodent , 2006, Nature Protocols.